SBIR/STTR Research Award
Lower Infectious Risk Donor Pigs for Xenotransplantation
Award amount
$368,111Program and phase
SBIR · Phase IIAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- BIOTRANSPLANT, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (Adapted from Applicant's Abstract): This is a new, fast track
application that explains the need for additional therapeutics for the
treatment of chronic hepatitis B virus (HBV) infection. Discovery of novel non
cytotoxic L-nucleosides with potent anti-HBV activity that, when used in
combination, act synergistically is described. These L-nucleosides are reported
to inhibit the viral DNA polymerase and replication without effect upon
cellular polymerases or mitocohndrial function and have been shown to
significantly reduce viral load in the chronic woodchuck hepatitis model.
Funding from SBIR phase 1 and 2 will be used to select and develop the
combination of the L-nucleosides with the greatest potential for
commercialization. Phase 1 will determine pharmacology, toxicology and
antiviral potency of two and three L nucleoside combinations in the woodchuck
chronic hepatitis model.
PROPOSED COMMERCIAL APPLICATION:
Chronic treatment of Hepatitis B virus infection. Delay in progression to cirrhosis and
hepatocellular carcinoma. Possible elimination of Hepatitis B virus.
Technology keywords
Not reported